VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
General Outlook
In simple terms, VistaGen Therapeutics, Inc. has 9.362 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 1.985% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.258%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.258%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust -3.089% return, is a testament to VistaGen Therapeutics, Inc.'s adeptness in optimizing resource deployment. VistaGen Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -2.684%. Furthermore, the proficiency of VistaGen Therapeutics, Inc. in capital utilization is underscored by a remarkable -4.233% return on capital employed.
Stock Prices
VistaGen Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $5.92, while its low point bottomed out at $5.1. This variance in figures offers investors a lucid insight into the roller-coaster ride that is VistaGen Therapeutics, Inc.'s stock market.
